rs80356503
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_001457.4(FLNB):c.5071G>A(p.Gly1691Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1691C) has been classified as Pathogenic.
Frequency
Consequence
NM_001457.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FLNB | NM_001457.4 | c.5071G>A | p.Gly1691Ser | missense_variant | 29/46 | ENST00000295956.9 | NP_001448.2 | |
FLNB | NM_001164317.2 | c.5164G>A | p.Gly1722Ser | missense_variant | 30/47 | NP_001157789.1 | ||
FLNB | NM_001164318.2 | c.5071G>A | p.Gly1691Ser | missense_variant | 29/46 | NP_001157790.1 | ||
FLNB | NM_001164319.2 | c.5071G>A | p.Gly1691Ser | missense_variant | 29/45 | NP_001157791.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FLNB | ENST00000295956.9 | c.5071G>A | p.Gly1691Ser | missense_variant | 29/46 | 1 | NM_001457.4 | ENSP00000295956.5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1691 of the FLNB protein (p.Gly1691Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with autosomal dominant Larsen syndrome or atelosteogenesis III (PMID: 14991055, 16648377, 16752402, 27048506). In at least one individual the variant was observed to be de novo. This variant is also known as p.Gly1722Ser. ClinVar contains an entry for this variant (Variation ID: 6406). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FLNB protein function with a negative predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Larsen syndrome Pathogenic:2Other:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2007 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Mar 19, 2024 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Larsen syndrome;C0265283:Atelosteogenesis type I;C0432201:Boomerang dysplasia;C1848934:Spondylocarpotarsal synostosis syndrome;C3668942:Atelosteogenesis type III Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PP3+PM6_Strong+PS4 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at